Yaupon locks up phase II Clearazide trial
Yaupon Therapeutics has completed enrollment for the second phase of its trial for Clearazide for early-stage cutaneous T-cell lymphoma.
Yaupon Therapeutics has completed enrollment for the second phase of its trial for Clearazide for early-stage cutaneous T-cell lymphoma.
The randomized study, slated for completion in 2010, has enrolled 260 patients from 13 cancer centers. Clearazide is a topical form of nitrogen mustard, an alkylating agent that works by inhibiting DNA replication.
Articles in this issue
New Doxil-based regimens don’t fly with FDA advisors
Four steps to improve the profitability of your oncology practice
Mathematical model predicts resistance to Herceptin
ASTRO issues guide on accelerated breast radiotherapy
Study renews breast ca link to migraines
Sutent shows promise for brain metastases in NSCLC patients
Abraxane, carboplatin pack one-two punch in two types of lung cancer
Discord prevails over pt privacy in clinical trials
Gastric adenocarcinoma: How to choose between postoperative chemoradiation and perioperative Rx?
Venous thrombotic events elevate chance of death in ALL, but no risk seen with AML
Expert panel reviews strategies for nutrition and cancer care
Office of Oncology Drug Products: A step ahead of the Obama transparency curve
Post-Rx surgery won’t boost OS in lung cancer
Siemens debuts RT plan platform
Exposure to pesticides raises myeloma risk
Recent Videos
